Lamivudine resistance in Iranian chronic hepatitis B patients

Shiraz E Medical Journal

Volumn 11, Issue 2, 2010, Pages 63-72

  Fallahian, F ^a   Alavian, S M ^b   Kayvani, H ^c   Alaeddini, F ^b   Zamani, F ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic hepatitis B; Lamivudine; Lamivudine Resistant mutations

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; HEPATITIS B(E) ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; VIRUS DNA;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; CHRONIC HEPATITIS; CLINICAL ARTICLE; DNA DETERMINATION; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; INCIDENCE; IRAN; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PROTEIN MOTIF; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; TREATMENT DURATION; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION;

EID: 77953002136     PISSN: 17351391     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol. 2002; 17: 409-414
2. Morgan M, Keeffe EB. Diagnosis and treatment of chronic hepatitis B: 2009 update. Minerva Gastroenterol Dietol 2009; 55: 5-22.
3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
4. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
5. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265-272.
6. Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol. 2008 Mar; 6 (3): 268-274
7. Zoulim F, Radenne S, Ducerf C. Liver Transpl. Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis. 2008 Oct; 14 Suppl 2: S1-7.
8. Yang DH, Liang WF, Xie YJ, Zhao NF, Fan J: PCR restriction length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine. Hepatobiliary Pancreat Dis Int. 2002; 1: 232-237 (Pubitemid 36748209)
9. Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antivir Ther. 2006; 11: 447-455 (Pubitemid 44024852)
10. Shin JW, Chung YH, Choi MH, Kim JA, Ryu SH, Jang MK, Kim IS, Park NH, Lee HC, Lee YS, Suh DJ. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy. J Gastroenterol Hepatol. 2005; 20: 844-849
11. Marrone A, Zampino R, Karayannis P, Cirillo G, Cesaro G, Guerrera B, Ricciotti R, del Giudice EM, Utili R, Adinolfi LE, Ruggiero G. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis. Aliment Pharmacol Ther. 2005; 22: 707-714
12. Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Watahiki S, Kumada H. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants. J Med Virol. 2006; 78: 341-352
13. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Takagi K, Kumada H. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology. 2003; 46:182-189
14. Heo J, Cho M, Cho BM, Lee SM, Kim TO, Kim GH, Kang DH, Song GA. Predictors of lamivudine resistance in patients with chronic hepatitis B virus infection. Korean J Hepatol. 2007; 13: 157-165
15. Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol. 2007; 13: 4085-4090
16. Ascione A, Ascione T, Lanza AG, Utech W, Di Costanzo GG, Macri M.Factors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis B. Hepatogastroenterology. 2006; 53: 919-923 (Pubitemid 44851228)
17. Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, Chen RY, Demediuk B, Shaw G, Bell SJ, Watson KJ, Locarnini SA, Desmond PV. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol. 2007; 22:1078-1085
18. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, Zoulim F.Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008 May; 48 (5): 747-755
19. Kazim SN, Chauhan R, Das BC, Sarin SK. J Gastroenterol Hepatol. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy. 2006 Oct; 21 (10): 1525-1532
20. Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine . Antivir Ther. 2003 Dec; 8 (6): 531-534
21. Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, Wong BC, Lai CL. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther. 2006;11 (6): 779-786 (Pubitemid 44497173)
22. Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C. J Viral Hepat. 2007 Nov;14 (11): 767-774
23. Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Chen DS, Kao JH. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir Ther. 2009;14(2): 203-210
24. Shin JW, Park NH, Jung SW, Park BR, Kim CJ, Jeong ID, Bang SJ, Kim do H. Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. Antivir Ther. 2009; 14 (2): 181-186
25. Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005; 2(1): 8-16.
26. Yim HJ. Hepatitis B virus genetic diversity and mutant] Korean J Hepatol. 2008 Dec; 14 (4): 446-464
27. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach. Gastroenterology. 2008 February; 134 (2): 405-415. doi:10.1053/j.gastro.2007.11.036.
28. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751.